期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地尔硫卓致他克莫司血药浓度升高2例 被引量：4

在线阅读 下载PDF
导出
摘要 他克莫（tacrolimus，FKS06，商品名为普乐可复）是日本藤泽药品工业公司从筑波链霉菌的发酵液中提取的一种23元环大环内酯类免疫抑制剂，目前广泛用于器官移植术后的免疫治疗，因其作用强，不良反应较环孢素A少，因而正在取代环孢素A成为器官移植术后首选的免疫抑制剂。地尔硫卓致环孢素血药浓度升高的报告较多见，但地尔硫卓致FK506血药浓度升高的报告较少。笔者在工作中观察到两例地尔硫卓引起FK506血药浓度升高的例子，报告如下。
作者 龚丽娴
机构地区 广州军区广州总医院药学部
出处 《医学信息》 2010年第6期1650-1650,共1页 Journal of Medical Information
关键词 血药浓度 地尔硫卓 大环内酯类免疫抑制剂 他克莫司 FK506 环孢素A 移植术后 FKS06
分类号 R969.1 [医药卫生—药理学]
  • 相关文献

参考文献4

二级参考文献23

  • 1郭平,李芚,廖工铁.环孢菌素临床药代动力学研究进展[J].中国药学杂志,1995,30(10):585-588. 被引量：19
  • 2Danovitch GM.Cyclosporin or tacrolimus which agent to choose[J].Nephrol Dial Transplant,1997,12:1566.
  • 3Vincenti F,Laskow DA,Neylan JF,et al.One-year follow up of an open-label trial of FK506 for primary kidney transplantation[J].Transplantation,1996,61:1576.
  • 4Przepivrka D,Nash RA,Wingard JR,et al.Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor ma transplantation[J].rrow Biol Blood Marrow Transplant,1999,5(2):94.
  • 5刘晓琰 施安国 费艳秋 等.免疫抑制剂国内外研究进展[J].上海医院药学,2000,11(3):14-14.
  • 6McMaster P,Mirza DF,Ismail T,et al.Therapeutic drug monitoring of tacrolimus in clinical transplantation[J].Ther Drug Monit,1995,17(3):602.
  • 7Hedayat S,Kershner RP,Su G.Relationship of whole blood FK506 concentrations to rejection and toxicity in liver and kidney transplants[J].J Biopharm Stat,1996,6(2):411.
  • 8Julia M P. Pharmacoeconomics of therapeutic drug monitoring in transplantation[ J], Ther Drug Monit ,2000,22( 1 ) :36 - 39.
  • 9Keown P,Niese D. Cyclosporine microsemulsion increase during exposure and educes acute rejection without incremental toxicity in denovo renal transplantation[J]. Kidney Int,1998,54(5) :938 -944.
  • 10Koup J R, Abel R B, Smithers J A, et al. Effect of age, gender and steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets [ J ]. Ther Drug Monit,1998,20(1) :73 -77.

共引文献14

同被引文献43

  • 1张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石.肾移植患者他克莫司血药浓度的影响因素[J].肾脏病与透析肾移植杂志,2005,14(4):333-338. 被引量：21
  • 2卫生部合理用药专家委员会.中国医师/药师临床用药指南[M].重庆:重庆出版社,2009.A1-A20.
  • 3Dai Y,Hebert MF,Isoherranen W,et al.Effect of polymorphism on tacrolimsms metabolic clearance in vitro[J].Drug Metab Dispos,2006,34(5):836-847.
  • 4Katsakiori PF,Papapetrou EP,SakeUaropoulos GC,et al.Factors affecting the long-term response to tacrolimus in renal transplant patients:pharmacokinetic and pharmacogenetic approach[J].Int J Med Sci,2010,7(2):94-100.
  • 5Roy JN,Barama A,Poirier C,et al.Cyp3A4,Cyp3A5 and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients[J].Pharmaeogenetics and Genomics,2006,16(9):659-665.
  • 6Mori T,Aisa Y,Kato J,et al.Drug interaction between voriconazole and calcineurin inhibitors in aliogeneic hematopoietic stem cell transplant recipients[J].Bone Marrow Transplantation,2009,44(6):371 -374.
  • 7Oellerich M,Armstrong VW.The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy:recent developments[J].Ther Drug Monit,2006,28(6):720-725.
  • 8Leather H,Boyette RM,Tian L,et al.Phannacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in aliogeneic hematopoietic stem cell transplant recipients[J].Biol Blood Marrow Transplant,2006,12 (3):325-334.
  • 9Takahashi K,Yano I,Fukuhara Y,et al.Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient[J].Drug Metab Pharmacokinet,2007,22(6):441 -444.
  • 10Hosohata K,Masuda S,Ogura Y,et al.Interaction between tacrolimus and lansoprazole,but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5[J].Drug Metab Pharmaco-kinet,2008,23(2):134-138.

引证文献4

二级引证文献38

医学信息
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部